If the absence of somatic TP53 mutations from CHEK2* BC genomes is a consequence of CHEK2 c.1100delC signaling through the TP53 pathway, this should be discernible from the CHEK2 pBC transcriptomes (Additional file 3: Table S8). The gene discussed is TP53; the disease is breast cancer.